Issued Patents 2016
Showing 25 most recent of 39 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 9522959 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-12-20 |
| 9518115 | Humanized anti-CD22 antibody | Chien-Hsing Chang | 2016-12-13 |
| 9513293 | Detection of early-stage pancreatic adenocarcinoma | David V. Gold | 2016-12-06 |
| 9498542 | Tetrameric cytokines with improved biological activity | Chien-Hsing Chang, Edmund A. Rossi | 2016-11-22 |
| 9499631 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-11-22 |
| 9492561 | Dock-and-Lock (DNL) Complexes for delivery of interference RNA | Chien-Hsing Chang | 2016-11-15 |
| 9493574 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-11-15 |
| 9493573 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-11-15 |
| 9492566 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2016-11-15 |
| 9486536 | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer | Serengulam V. Govindan, William J. McBride, Nalini Sathyanarayan, Christine Mazza-Ferreira | 2016-11-08 |
| 9481732 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-11-01 |
| 9481878 | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity | Chien-Hsing Chang, Edmund A. Rossi | 2016-11-01 |
| 9480756 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2016-11-01 |
| 9475883 | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis | Chien-Hsing Chang, Hans J. Hansen, Edmund A. Rossi | 2016-10-25 |
| 9475884 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-10-25 |
| 9468689 | Ultrafiltration concentration of allotype selected antibodies for small-volume administration | Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen | 2016-10-18 |
| 9457100 | PEGylation by the dock and lock (DNL) technique | Chien-Hsing Chang, William J. McBride, Edmund A. Rossi | 2016-10-04 |
| 9458242 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2016-10-04 |
| 9457072 | Dock-and-lock (DNL) vaccines for cancer therapy | Chien-Hsing Chang | 2016-10-04 |
| 9452228 | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) | Donglin Liu, Chien-Hsing Chang | 2016-09-27 |
| 9446123 | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy | Edmund A. Rossi, Chien-Hsing Chang | 2016-09-20 |
| 9441043 | Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R) | Chien-Hsing Chang, Michele J. Losman | 2016-09-13 |
| 9416197 | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease | Rongxiu Li, Chien-Hsing Chang | 2016-08-16 |
| 9382329 | Disease therapy by inducing immune response to Trop-2 expressing cells | Chien-Hsing Chang, Edmund A. Rossi, Diane Rossi | 2016-07-05 |
| 9375489 | Antibody-SN-38 immunoconjugates with a CL2A linker | Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman | 2016-06-28 |